ArticleOrganometallics2026
A Tutorial on the Mechanisms of Group 9 Transition-Metal-Catalyzed Asymmetric Olefin Hydrogenation.
Article in Organometallics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asymmetric alkene hydrogenation catalyzed by group 9 transition-metal complexes has become one of the most widely used methods for producing enantio-enriched compounds, particularly single-enantiomer pharmaceuticals. This Tutorial is focused on the mechanistic aspects of asymmetric alkene hydrogenation mediated by group 9 transition-metal catalysts with an emphasis on elucidating reaction pathways and the origins of enantio-induction. Among these catalysts, bis-(phosphine)-rhodium-(I) complexes are the most extensively studied, due to their broad applicability and historical importance in the development of asymmetric hydrogenation. Early mechanistic studies provided strong support for an unsaturated pathway consistent with the Curtin-Hammett principle, in which the minor rhodium alkene diastereomer reacts more rapidly with H
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.